Business Context and Reporting Period
This Form 8-K is a current report filed by Liminatus Pharma, Inc. (Nasdaq: LIMN, LIMNW) on June 4, 2025, covering events occurring between May 29, 2025, and June 3, 2025. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a notice of delisting compliance and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
- Non-Compliance Notice: On May 29, 2025, the Company received a notice from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to a delay in filing its Form 10-Q for the quarter ended March 31, 2025.
- Resolution: The Company filed the delinquent Form 10-Q on June 2, 2025.
- Regained Compliance: On June 3, 2025, Nasdaq confirmed the Company had regained compliance, and the matter was closed.
Outlook, Risks, and Management Commentary
The filing addresses a specific regulatory risk regarding continued listing standards. Management confirmed the timely submission of the overdue quarterly report to resolve the issue. No forward-looking guidance, strategic outlook, or discussion of other contingencies is provided in this document.
Investor Verification Checklist
- Verify the content of the Form 10-Q for the period ended March 31, 2025, filed on June 2, 2025, to understand the financial condition that caused the delay.
- Confirm the Company's current standing on Nasdaq to ensure no further listing deficiencies exist.
- Review the press release dated June 4, 2025 (Exhibit 99.7) for any additional public disclosures regarding the delay.